SUPN – Supernus Pharmaceuticals Inc

SUPN — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

8.6

Margin Of Safety %

-18

Put/Call OI Ratio

2.64

EPS Next Q Diff

0.81

EPS Last/This Y

3.35

EPS This/Next Y

1.69

Price

49.43

Target Price

62.83

Analyst Recom

1.43

Performance Q

-2.77

Upside

-136.1%

Beta

0.58

Ticker: SUPN

18 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-04-20	SUPN	51.27	3.22	0.25	1594
2026-04-23	SUPN	50.41	3.19	0.00	1599
2026-04-24	SUPN	49.77	3.19	0.78	1598
2026-04-27	SUPN	49.51	3.16	0.20	1610
2026-04-28	SUPN	48.68	3.16	0.20	1610
2026-04-29	SUPN	48.53	3.16	0.20	1610
2026-04-30	SUPN	48	2.82	0.33	1671
2026-05-01	SUPN	47.84	2.80	0.75	1675
2026-05-04	SUPN	48.59	2.78	999.99	1681
2026-05-05	SUPN	49.15	2.96	0.02	1762
2026-05-06	SUPN	51.43	2.66	0.19	1812
2026-05-07	SUPN	52.23	2.66	0.19	1812
2026-05-08	SUPN	51.54	2.64	3.00	1813
2026-05-11	SUPN	49.34	2.64	3.00	1813
2026-05-12	SUPN	50.57	2.64	3.00	1813
2026-05-13	SUPN	51.38	2.64	999.99	1819
2026-05-14	SUPN	51.17	2.64	999.99	1819
2026-05-15	SUPN	49.46	2.64	0.00	1821
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

18 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-04-16	SUPN	49.27	-41.5	-	2.37
2026-04-17	SUPN	51.41	-41.5	-	2.37
2026-04-20	SUPN	51.25	-41.5	-	2.37
2026-04-21	SUPN	49.14	-41.5	-	2.37
2026-04-22	SUPN	50.29	-41.5	-	2.37
2026-04-23	SUPN	50.37	-41.5	-	2.37
2026-04-24	SUPN	49.74	-37.0	-	2.34
2026-04-27	SUPN	49.47	-37.0	-	2.34
2026-04-28	SUPN	48.63	-37.0	-	2.34
2026-04-30	SUPN	48.00	-37.0	-	2.34
2026-05-01	SUPN	47.85	-37.0	-	2.34
2026-05-04	SUPN	48.60	-37.0	-	2.34
2026-05-05	SUPN	49.11	-37.0	-	2.34
2026-05-06	SUPN	51.36	-37.0	-	2.34
2026-05-07	SUPN	52.22	-37.0	-	2.34
2026-05-08	SUPN	51.54	-37.0	-	2.34
2026-05-11	SUPN	49.33	-48.1	-	2.48
2026-05-12	SUPN	50.55	-48.1	-	2.48
2026-05-13	SUPN	51.34	-48.1	-	2.67
2026-05-14	SUPN	51.21	-48.1	-	2.67
2026-05-15	SUPN	49.43	-48.1	-	2.67
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

22 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-04-16	SUPN	-6.09	-5.19	8.32
2026-04-17	SUPN	-6.09	-5.19	8.32
2026-04-20	SUPN	-6.09	-5.14	8.32
2026-04-21	SUPN	-6.09	-5.14	8.32
2026-04-22	SUPN	-6.09	-5.14	8.32
2026-04-23	SUPN	-6.09	-5.14	8.32
2026-04-24	SUPN	-6.06	-5.14	8.32
2026-04-27	SUPN	-6.06	-3.66	8.69
2026-04-28	SUPN	-6.06	-3.66	8.69
2026-04-29	SUPN	-6.06	-3.66	8.69
2026-04-30	SUPN	-6.06	-3.66	8.69
2026-05-01	SUPN	-6.06	-3.66	8.69
2026-05-04	SUPN	-6.06	-4.87	8.69
2026-05-05	SUPN	-6.06	-4.87	8.69
2026-05-06	SUPN	-6.06	-4.87	8.69
2026-05-07	SUPN	-6.06	-4.87	8.69
2026-05-08	SUPN	-6.02	-4.87	8.62
2026-05-11	SUPN	-6.02	-4.85	8.62
2026-05-12	SUPN	-6.02	-4.85	8.60
2026-05-13	SUPN	-6.02	-4.85	8.60
2026-05-14	SUPN	-6.02	-4.85	8.60
2026-05-15	SUPN	-6.02	-4.85	8.60
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

22 items 1 of 1

Last Quarter Act. EPS

-0.11

Avg. EPS Est. Current Quarter

0.47

Avg. EPS Est. Next Quarter

0.7

Insider Transactions

-6.02

Institutional Transactions

-4.85

Beta

0.58

Average Sales Estimate Current Quarter

205

Average Sales Estimate Next Quarter

220

Fair Value

40.31

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

17.2

Max Drawdown 5-Year %

-45.9

Target Price

62.83

P/E

Forward P/E

12.55

PEG

0.68

P/S

3.69

P/B

2.66

P/Free Cash Flow

34.88

EPS

-0.51

Average EPS Est. Cur. Y

2.67

EPS Next Y. (Est.)

4.37

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-3.74

Relative Volume

0.85

Return on Equity vs Sector %

-29.6

Return on Equity vs Industry %

-10.7

EPS 1 7Days Diff

0.3

EPS 1 30Days Diff

0.31

EBIT Estimation

◆ SUPN Healthcare

$49.43

📉

Swing / Pullback

Buy the dip on strong trends

WEAK

Trend

6/20

Pullback

9/25

Volume

7/15

Valuation

15/20

TP/AR

2/10

Options

3/10

RSI

46.6

Range 1M

44.5%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

5/25

Growth

18/30

Estimates

3/20

Inst/Vol

1/15

Options

4/10

EPS Yr

-23.4%

EPS NY

59%

52W%

65%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +104.6% upside

Quality

6/30

Valuation

19/30

Growth

12/25

Stability

6/10

LT Trend

2/5

Upside

+104.6%

Quality

MoS

-18%

Supernus Pharmaceuticals, Inc.

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Employees: 778

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; and SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland.

SUPN

Latest News

—

Caricamento notizie per SUPN…

stock quote shares SUPN – Supernus Pharmaceuticals Inc Stock Price stock today

news today SUPN – Supernus Pharmaceuticals Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch SUPN – Supernus Pharmaceuticals Inc yahoo finance google finance

stock history SUPN – Supernus Pharmaceuticals Inc invest stock market

stock prices SUPN premarket after hours

ticker SUPN fair value insiders trading

OGI – OrganiGram Holdings Inc.

OGI — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

4.32

Margin Of Safety %

Put/Call OI Ratio

0.11

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

-0.04

Price

1.07

Target Price

2.24

Analyst Recom

1.4

Performance Q

-17.05

Upside

-270.1%

Beta

1.45

Ticker: OGI

18 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-04-20	OGI	1.5	0.09	0.18	13472
2026-04-23	OGI	1.43	0.10	0.11	15908
2026-04-24	OGI	1.445	0.10	6.00	16284
2026-04-27	OGI	1.44	0.11	0.01	16451
2026-04-28	OGI	1.4	0.11	0.00	16547
2026-04-29	OGI	1.365	0.11	0.42	16749
2026-04-30	OGI	1.415	0.11	0.22	16952
2026-05-01	OGI	1.415	0.11	0.00	17043
2026-05-04	OGI	1.395	0.11	0.65	17057
2026-05-05	OGI	1.39	0.12	0.03	17237
2026-05-06	OGI	1.39	0.12	0.01	17245
2026-05-07	OGI	1.38	0.12	0.00	17347
2026-05-08	OGI	1.37	0.12	0.00	17119
2026-05-11	OGI	1.31	0.12	1.75	17199
2026-05-12	OGI	1.115	0.12	0.04	17361
2026-05-13	OGI	1.11	0.11	0.11	16916
2026-05-14	OGI	1.09	0.11	0.01	17078
2026-05-15	OGI	1.065	0.11	0.07	16991
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

18 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-04-16	OGI	1.51	-	-	0.10
2026-04-17	OGI	1.46	-	-	0.10
2026-04-20	OGI	1.50	-	-	0.10
2026-04-21	OGI	1.44	-	-	0.10
2026-04-22	OGI	1.58	-	-	0.10
2026-04-23	OGI	1.43	-	-	0.10
2026-04-24	OGI	1.45	-	-	0.10
2026-04-27	OGI	1.45	-	-	0.09
2026-04-28	OGI	1.40	-	-	0.09
2026-04-30	OGI	1.41	-	-	0.09
2026-05-01	OGI	1.41	-	-	0.09
2026-05-04	OGI	1.39	-	-	0.07
2026-05-05	OGI	1.39	-	-	0.07
2026-05-06	OGI	1.39	-	-	0.07
2026-05-07	OGI	1.38	-	-	0.07
2026-05-08	OGI	1.37	-	-	0.07
2026-05-11	OGI	1.32	-	-	0.07
2026-05-12	OGI	1.12	-	-	0.07
2026-05-13	OGI	1.11	-	-	0.07
2026-05-14	OGI	1.09	-	-	0.07
2026-05-15	OGI	1.07	-	-	0.07
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

22 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-04-16	OGI	0.00	1.36	3.88
2026-04-17	OGI	0.00	1.36	3.88
2026-04-20	OGI	0.00	1.31	3.88
2026-04-21	OGI	0.00	1.31	3.88
2026-04-22	OGI	0.00	1.31	3.88
2026-04-23	OGI	0.00	1.31	3.88
2026-04-24	OGI	0.00	1.31	3.95
2026-04-27	OGI	0.00	2.87	4.15
2026-04-28	OGI	0.00	2.87	4.15
2026-04-29	OGI	0.00	2.87	4.15
2026-04-30	OGI	0.00	2.87	4.15
2026-05-01	OGI	0.00	2.87	4.15
2026-05-04	OGI	0.00	2.67	4.15
2026-05-05	OGI	0.00	2.67	4.15
2026-05-06	OGI	0.00	2.67	4.15
2026-05-07	OGI	0.00	2.67	4.15
2026-05-08	OGI	0.00	2.67	4.15
2026-05-11	OGI	0.00	2.63	4.15
2026-05-12	OGI	0.00	2.63	4.32
2026-05-13	OGI	0.00	2.63	4.32
2026-05-14	OGI	0.00	2.63	4.32
2026-05-15	OGI	0.00	2.63	4.32
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

22 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

-0.01

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

2.63

Beta

1.45

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

92.4

Max Drawdown 5-Year %

-93.3

Target Price

2.24

P/E

Forward P/E

31.84

PEG

P/S

0.74

P/B

0.55

P/Free Cash Flow

EPS

-0.14

Average EPS Est. Cur. Y

0.07

EPS Next Y. (Est.)

0.02

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-9.31

Relative Volume

1.78

Return on Equity vs Sector %

-22

Return on Equity vs Industry %

-3.1

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.06

EBIT Estimation

◆ OGI Healthcare

$1.07

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

16/20

Pullback

5/25

Volume

3/15

Valuation

15/20

TP/AR

4/10

Options

8/10

RSI

25.6

Range 1M

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

14/25

Growth

13/30

Estimates

4/20

Inst/Vol

7/15

Options

8/10

EPS Yr

170.2%

EPS NY

-64.6%

52W%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🔴 SELL -22.8% upside

Quality

2/30

Valuation

2/30

Growth

8/25

Stability

7/10

LT Trend

4/5

Upside

-22.8%

Quality

Organigram Global Inc.

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Employees: 1137

Organigram Global Inc. engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, beverages, gummies, and concentrates; and adult use recreational cannabis under the SHRED, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Boxhot, Edison JOLTS, Wola, Rizzlers, DEBUNK, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings and dried flowers to other licensed producers. It sells cannabis products to wholesale and retail channels in the recreational and medical cannabis regimes, as well as through online. Organigram Global Inc. was formerly known as Organigram Holdings Inc. and changed its name to Organigram Global Inc. in March 2025. The company is headquartered in Toronto, Canada.

OGI

Latest News

—

Caricamento notizie per OGI…

stock quote shares OGI – OrganiGram Holdings Inc. Stock Price stock today

news today OGI – OrganiGram Holdings Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch OGI – OrganiGram Holdings Inc. yahoo finance google finance

stock history OGI – OrganiGram Holdings Inc. invest stock market

stock prices OGI premarket after hours

ticker OGI fair value insiders trading

MURA – Mural Oncology plc

MURA — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

2.66

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

2.04

Target Price

Analyst Recom

Performance Q

-1.45

Upside

N/A

Beta

2.88

Ticker: MURA

18 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-04-20	MURA	2.04	N/A	N/A	0
2026-04-23	MURA	2.04	N/A	N/A	0
2026-04-24	MURA	2.04	N/A	N/A	0
2026-04-27	MURA	2.04	N/A	N/A	0
2026-04-28	MURA	2.04	N/A	N/A	0
2026-04-29	MURA	2.04	N/A	N/A	0
2026-04-30	MURA	2.04	N/A	N/A	0
2026-05-01	MURA	2.04	N/A	N/A	0
2026-05-04	MURA	2.04	N/A	N/A	0
2026-05-05	MURA	2.04	N/A	N/A	0
2026-05-06	MURA	2.04	N/A	N/A	0
2026-05-07	MURA	2.04	N/A	N/A	0
2026-05-08	MURA	2.04	N/A	N/A	0
2026-05-11	MURA	2.04	N/A	N/A	0
2026-05-12	MURA	2.04	N/A	N/A	0
2026-05-13	MURA	2.04	N/A	N/A	0
2026-05-14	MURA	2.04	N/A	N/A	0
2026-05-15	MURA	2.04	N/A	N/A	0
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

18 items 1 of 1

Last Quarter Act. EPS

-0.21

Avg. EPS Est. Current Quarter

-0.37

Avg. EPS Est. Next Quarter

Insider Transactions

-2.62

Institutional Transactions

-16.45

Beta

2.88

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

0.64

P/Free Cash Flow

EPS

-6.93

Average EPS Est. Cur. Y

EPS Next Y. (Est.)

-0.39

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

-242.8

Return on Equity vs Industry %

-227.7

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

No data found for MURA

MURA

Latest News

—

Caricamento notizie per MURA…

stock quote shares MURA – Mural Oncology plc Stock Price stock today

news today MURA – Mural Oncology plc stock forecast ,stock prediction 2023 2024 2025

marketwatch MURA – Mural Oncology plc yahoo finance google finance

stock history MURA – Mural Oncology plc invest stock market

stock prices MURA premarket after hours

ticker MURA fair value insiders trading

EVOK – Evoke Pharma Inc

EVOK — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

0.73

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

2.56

Price

Target Price

Analyst Recom

Performance Q

116.11

Upside

N/A

Beta

-0.1

Ticker: EVOK

18 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-04-20	EVOK	11	N/A	N/A	0
2026-04-23	EVOK	11	N/A	N/A	0
2026-04-24	EVOK	11	N/A	N/A	0
2026-04-27	EVOK	11	N/A	N/A	0
2026-04-28	EVOK	11	N/A	N/A	0
2026-04-29	EVOK	11	N/A	N/A	0
2026-04-30	EVOK	11	N/A	N/A	0
2026-05-01	EVOK	11	N/A	N/A	0
2026-05-04	EVOK	11	N/A	N/A	0
2026-05-05	EVOK	11	N/A	N/A	0
2026-05-06	EVOK	11	N/A	N/A	0
2026-05-07	EVOK	11	N/A	N/A	0
2026-05-08	EVOK	11	N/A	N/A	0
2026-05-11	EVOK	11	N/A	N/A	0
2026-05-12	EVOK	11	N/A	N/A	0
2026-05-13	EVOK	11	N/A	N/A	0
2026-05-14	EVOK	11	N/A	N/A	0
2026-05-15	EVOK	11	N/A	N/A	0
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

18 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

-0.3

Avg. EPS Est. Next Quarter

Insider Transactions

-3.69

Institutional Transactions

Beta

-0.1

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

98.4

Max Drawdown 5-Year %

-99.7

Target Price

P/E

Forward P/E

PEG

P/S

1.31

P/B

5.64

P/Free Cash Flow

EPS

-2.38

Average EPS Est. Cur. Y

-1.88

EPS Next Y. (Est.)

0.68

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-36.23

Relative Volume

Return on Equity vs Sector %

-166.4

Return on Equity vs Industry %

-162.7

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.08

EBIT Estimation

No data found for EVOK

EVOK

Latest News

—

Caricamento notizie per EVOK…

stock quote shares EVOK – Evoke Pharma Inc Stock Price stock today

news today EVOK – Evoke Pharma Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch EVOK – Evoke Pharma Inc yahoo finance google finance

stock history EVOK – Evoke Pharma Inc invest stock market

stock prices EVOK premarket after hours

ticker EVOK fair value insiders trading

AMPH – Amphastar Pharmaceuticals Inc

AMPH — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

10.82

Margin Of Safety %

Put/Call OI Ratio

0.04

EPS Next Q Diff

0.6

EPS Last/This Y

0.74

EPS This/Next Y

0.46

Price

16.88

Target Price

23.33

Analyst Recom

Performance Q

-40.81

Upside

244.4%

Beta

0.91

Ticker: AMPH

18 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-04-20	AMPH	22.95	0.04	0.00	1139
2026-04-23	AMPH	21.01	0.04	0.00	1199
2026-04-24	AMPH	21.43	0.04	0.00	1199
2026-04-27	AMPH	21.66	0.04	0.00	1200
2026-04-28	AMPH	21.84	0.04	0.00	1200
2026-04-29	AMPH	21.6	0.04	0.00	1200
2026-04-30	AMPH	21.96	0.04	0.00	1200
2026-05-01	AMPH	21.89	0.04	0.00	1202
2026-05-04	AMPH	22.73	0.04	0.00	1202
2026-05-05	AMPH	23.38	0.04	0.06	1225
2026-05-06	AMPH	23.91	0.04	0.00	1240
2026-05-07	AMPH	24.04	0.04	0.62	1240
2026-05-08	AMPH	18.99	0.05	0.55	1270
2026-05-11	AMPH	18.44	0.06	0.00	1294
2026-05-12	AMPH	17.5	0.06	3.00	1294
2026-05-13	AMPH	18.33	0.06	0.25	1294
2026-05-14	AMPH	17.29	0.04	0.20	1275
2026-05-15	AMPH	16.87	0.04	0.20	1275
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

18 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-04-16	AMPH	21.80	-2.3	-	3.27
2026-04-17	AMPH	22.84	-2.3	-	3.27
2026-04-20	AMPH	22.94	-2.3	-	3.27
2026-04-21	AMPH	21.22	-2.3	-	3.27
2026-04-22	AMPH	20.99	-2.3	-	3.27
2026-04-23	AMPH	21.01	-2.3	-	3.27
2026-04-24	AMPH	21.45	-4.7	-	3.25
2026-04-27	AMPH	21.68	-4.7	-	3.25
2026-04-28	AMPH	21.85	-4.7	-	3.25
2026-04-30	AMPH	21.95	-4.7	-	3.25
2026-05-01	AMPH	21.89	-4.7	-	3.25
2026-05-04	AMPH	22.73	-4.7	-	3.25
2026-05-05	AMPH	23.38	-4.7	-	3.25
2026-05-06	AMPH	23.91	-4.7	-	3.25
2026-05-07	AMPH	24.00	-4.7	-	3.25
2026-05-08	AMPH	18.99	-4.7	-	3.25
2026-05-11	AMPH	18.45	-4.7	-	3.25
2026-05-12	AMPH	17.50	-4.7	-	2.97
2026-05-13	AMPH	18.34	-4.7	-	2.97
2026-05-14	AMPH	17.28	-4.7	-	2.84
2026-05-15	AMPH	16.88	-4.7	-	2.84
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

22 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-04-16	AMPH	-0.28	1.97	10.75
2026-04-17	AMPH	-0.28	1.97	10.75
2026-04-20	AMPH	-0.28	2.03	10.75
2026-04-21	AMPH	-0.28	2.03	10.75
2026-04-22	AMPH	-0.28	2.03	10.91
2026-04-23	AMPH	-0.27	2.03	10.91
2026-04-24	AMPH	-0.27	2.03	10.91
2026-04-27	AMPH	-0.27	1.95	12.08
2026-04-28	AMPH	-0.27	1.95	12.08
2026-04-29	AMPH	-0.27	1.95	12.31
2026-04-30	AMPH	-0.27	1.95	12.31
2026-05-01	AMPH	-0.27	1.95	12.31
2026-05-04	AMPH	-0.27	0.86	12.31
2026-05-05	AMPH	-0.27	0.86	12.31
2026-05-06	AMPH	-0.27	0.86	12.31
2026-05-07	AMPH	-0.27	0.86	12.31
2026-05-08	AMPH	-0.27	0.86	12.31
2026-05-11	AMPH	-0.27	0.52	11.78
2026-05-12	AMPH	-0.32	0.52	10.82
2026-05-13	AMPH	-0.32	0.52	10.82
2026-05-14	AMPH	-0.32	0.52	10.82
2026-05-15	AMPH	-0.32	0.52	10.82
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

22 items 1 of 1

Last Quarter Act. EPS

0.26

Avg. EPS Est. Current Quarter

0.68

Avg. EPS Est. Next Quarter

0.86

Insider Transactions

-0.32

Institutional Transactions

0.52

Beta

0.91

Average Sales Estimate Current Quarter

174

Average Sales Estimate Next Quarter

182

Fair Value

28.31

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

75.1

Max Drawdown 5-Year %

-73.4

Target Price

23.33

P/E

10.13

Forward P/E

5.15

PEG

3.36

P/S

1.03

P/B

0.97

P/Free Cash Flow

5.5

EPS

1.66

Average EPS Est. Cur. Y

2.84

EPS Next Y. (Est.)

3.3

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

1.14

Return on Equity vs Sector %

-16.7

Return on Equity vs Industry %

2.2

EPS 1 7Days Diff

-0.4

EPS 1 30Days Diff

-0.47

EBIT Estimation

◆ AMPH Healthcare

$16.87

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

20/20

Pullback

13/25

Volume

1/15

Valuation

18/20

TP/AR

0/10

Options

7/10

RSI

31.3

Range 1M

2.5%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

7/25

Growth

6/30

Estimates

5/20

Inst/Vol

5/15

Options

10/10

EPS Yr

-13.5%

EPS NY

16.6%

52W%

1.3%

💎

Long-Term Value

Quality companies, undervalued

WEAK

🟢 BUY +320.3% upside

Quality

9/30

Valuation

25/30

Growth

6/25

Stability

6/10

LT Trend

4/5

Upside

+320.3%

Quality

MoS

68%

Amphastar Pharmaceuticals, Inc.

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Employees: 1976

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

AMPH

Latest News

—

Caricamento notizie per AMPH…

stock quote shares AMPH – Amphastar Pharmaceuticals Inc Stock Price stock today

news today AMPH – Amphastar Pharmaceuticals Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch AMPH – Amphastar Pharmaceuticals Inc yahoo finance google finance

stock history AMPH – Amphastar Pharmaceuticals Inc invest stock market

stock prices AMPH premarket after hours

ticker AMPH fair value insiders trading

ALKS – Alkermes plc

ALKS — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

12.08

Margin Of Safety %

-25

Put/Call OI Ratio

0.91

EPS Next Q Diff

0.76

EPS Last/This Y

-0.04

EPS This/Next Y

0.92

Price

37.47

Target Price

45.44

Analyst Recom

1.44

Performance Q

13.03

Upside

-16.0%

Beta

0.34

Ticker: ALKS

18 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-04-20	ALKS	34.22	1.54	0.08	6442
2026-04-23	ALKS	33.92	1.45	0.82	6712
2026-04-24	ALKS	33.3	1.44	0.20	6769
2026-04-27	ALKS	33.7	1.43	0.08	6806
2026-04-28	ALKS	34.1	1.20	0.13	7360
2026-04-29	ALKS	33.72	1.16	0.59	7543
2026-04-30	ALKS	33.7	1.15	1.80	7660
2026-05-01	ALKS	33.37	1.15	6.00	7708
2026-05-04	ALKS	34.14	1.17	1.41	7762
2026-05-05	ALKS	36.26	1.20	0.34	7765
2026-05-06	ALKS	35.31	1.06	0.09	8660
2026-05-07	ALKS	35.4	1.06	0.08	8708
2026-05-08	ALKS	35	1.04	0.20	8814
2026-05-11	ALKS	35.48	1.04	0.14	8822
2026-05-12	ALKS	38.3	1.05	0.37	8790
2026-05-13	ALKS	38.93	0.76	0.28	12345
2026-05-14	ALKS	38.38	0.79	0.98	13165
2026-05-15	ALKS	37.47	0.91	0.02	13593
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

18 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-04-16	ALKS	33.76	-26.9	160.8	2.35
2026-04-17	ALKS	34.51	-26.9	172.2	2.35
2026-04-20	ALKS	34.21	-26.9	167.6	2.35
2026-04-21	ALKS	33.51	-113.7	156.9	0.06
2026-04-22	ALKS	33.75	-113.7	160.6	0.06
2026-04-23	ALKS	33.91	-113.7	163.1	0.06
2026-04-24	ALKS	33.30	-113.7	153.8	0.06
2026-04-27	ALKS	33.73	-113.7	160.3	0.06
2026-04-28	ALKS	34.15	-113.7	166.6	0.06
2026-04-30	ALKS	33.72	-113.7	160.2	0.06
2026-05-01	ALKS	33.38	-113.7	154.9	0.06
2026-05-04	ALKS	34.15	-113.7	166.7	0.06
2026-05-05	ALKS	36.26	-113.7	198.6	0.06
2026-05-06	ALKS	35.30	-113.7	153.3	0.06
2026-05-07	ALKS	35.40	-92.6	-	0.06
2026-05-08	ALKS	35.00	-92.6	-	0.06
2026-05-11	ALKS	35.48	-	-	-0.56
2026-05-12	ALKS	38.30	-72.7	-	0.98
2026-05-13	ALKS	38.91	-51.6	-	0.98
2026-05-14	ALKS	38.36	-51.6	-	1.43
2026-05-15	ALKS	37.47	-51.6	-	1.43
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

22 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-04-16	ALKS	-3.81	3.29	11.67
2026-04-17	ALKS	-3.81	3.29	11.67
2026-04-20	ALKS	-3.81	3.27	11.67
2026-04-21	ALKS	-3.81	3.27	11.67
2026-04-22	ALKS	-3.81	3.27	11.65
2026-04-23	ALKS	-4.16	3.27	11.65
2026-04-24	ALKS	-4.16	3.27	11.65
2026-04-27	ALKS	-4.16	2.60	12.06
2026-04-28	ALKS	-4.16	2.60	12.06
2026-04-29	ALKS	-4.16	2.60	12.06
2026-04-30	ALKS	-4.16	2.60	12.06
2026-05-01	ALKS	-4.16	2.60	12.06
2026-05-04	ALKS	-4.16	2.19	12.06
2026-05-05	ALKS	-4.23	2.19	12.06
2026-05-06	ALKS	-4.23	2.19	12.06
2026-05-07	ALKS	-4.23	2.19	12.06
2026-05-08	ALKS	-4.22	2.19	12.03
2026-05-11	ALKS	-4.24	2.31	12.03
2026-05-12	ALKS	-4.22	2.31	12.08
2026-05-13	ALKS	-4.22	2.31	12.08
2026-05-14	ALKS	-4.22	2.31	12.08
2026-05-15	ALKS	-4.22	2.31	12.08
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

22 items 1 of 1

Last Quarter Act. EPS

-0.4

Avg. EPS Est. Current Quarter

0.33

Avg. EPS Est. Next Quarter

0.36

Insider Transactions

-4.22

Institutional Transactions

2.31

Beta

0.34

Average Sales Estimate Current Quarter

458

Average Sales Estimate Next Quarter

473

Fair Value

28.23

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

5.3

Max Drawdown 5-Year %

-33.2

Target Price

45.44

P/E

41.67

Forward P/E

60.01

PEG

P/S

P/B

3.56

P/Free Cash Flow

28.17

EPS

0.9

Average EPS Est. Cur. Y

1.43

EPS Next Y. (Est.)

2.35

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

9.78

Relative Volume

0.55

Return on Equity vs Sector %

-18.2

Return on Equity vs Industry %

0.7

EPS 1 7Days Diff

1.4

EPS 1 30Days Diff

1.37

EBIT Estimation

◆ ALKS Healthcare

$37.48

📉

Swing / Pullback

Buy the dip on strong trends

WEAK

Trend

0/20

Pullback

2/25

Volume

8/15

Valuation

11/20

TP/AR

5/10

Options

5/10

RSI

62.7

Range 1M

71.1%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

7/25

Growth

17/30

Estimates

10/20

Inst/Vol

7/15

Options

5/10

EPS Yr

-117%

EPS NY

356.5%

52W%

86.5%

💎

Long-Term Value

Quality companies, undervalued

WEAK

🟢 BUY +56.6% upside

Quality

8/30

Valuation

13/30

Growth

14/25

Stability

6/10

LT Trend

1/5

Upside

+56.6%

Quality

MoS

-25%

Alkermes plc

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Employees: 2050

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

ALKS

Latest News

—

Caricamento notizie per ALKS…

stock quote shares ALKS – Alkermes plc Stock Price stock today

news today ALKS – Alkermes plc stock forecast ,stock prediction 2023 2024 2025

marketwatch ALKS – Alkermes plc yahoo finance google finance

stock history ALKS – Alkermes plc invest stock market

stock prices ALKS premarket after hours

ticker ALKS fair value insiders trading

No more stocks to show

SUPN – Supernus Pharmaceuticals Inc

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: SUPN

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

OGI – OrganiGram Holdings Inc.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: OGI

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y